10,787 results match your criteria Natriuretic Peptides in Congestive Heart Failure


Adiponectin and cardiometabolic trait and mortality: where do we go?

Cardiovasc Res 2021 Jun 12. Epub 2021 Jun 12.

Division of Cardiovascular Disease, Gachon University Gil Hospital, Incheon, Korea, Gachon Cardiovascular Research Institute, Incheon, Korea.

Adiponectin is an adipocyte-derived cytokine known for its cardioprotective effects in preclinical studies. Early epidemiologic studies replicated these findings and drew great interest. Subsequent large-scale prospective cohorts, however, showed that adiponectin levels seemed not to relate to incident coronary artery disease (CAD). Read More

View Article and Full-Text PDF

[Biomarkers in Heart Failure: Current and Future].

Kardiologiia 2021 May 31;61(5):4-16. Epub 2021 May 31.

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow.

Heart failure (HF) is the ending of practically all cardiovascular diseases and the reason for hospitalization of 49% of patients in a cardiological hospital. Available instrumental diagnostic methods and biomarkers not always allow verification of HF, particularly in patients with preserved left ventricular ejection fraction. Prediction of chronic HF in patients with risk factors faces great difficulties. Read More

View Article and Full-Text PDF

Natriuretic Peptide Clearance Receptor (NPR-C) Pathway as a Novel Therapeutic Target in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF).

Front Physiol 2021 21;12:674254. Epub 2021 May 21.

Institut du Savoir Montfort, Hôpital Montfort, University of Ottawa, Ottawa, ON, Canada.

Heart failure (HF) with preserved ejection fraction (HFpEF) is a major public health problem with cases projected to double over the next two decades. There are currently no US Food and Drug Administration-approved therapies for the health-related outcomes of HFpEF. However, considering the high prevalence of this heterogeneous syndrome, a directed therapy for HFpEF is one the greatest unmet needs in cardiovascular medicine. Read More

View Article and Full-Text PDF

Performances of a novel chemiluninescence ABEI-based NT-proBNP immunoassay.

Acta Cardiol 2021 Jun 2:1-4. Epub 2021 Jun 2.

Department of Clinical Biochemistry, Cliniques Universitaires St-Luc and Université Catholique de Louvain, Brussels, Belgium.

Natriuretic peptides are widely used in clinical practice as cardiac markers for early diagnosis, prognosis and for the monitoring of treatment efficiency of heart Failure (HF). According to the clinical relevance of natriuretic peptides testing, it is important to assess the performances of novel platform for testing. Our study showed the overall good performances of a new NT-proBNP ABEI-based automated immunoassay. Read More

View Article and Full-Text PDF

Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options.

Expert Opin Pharmacother 2021 Jun 9:1-9. Epub 2021 Jun 9.

Centre Hospitalier Universitaire de Nancy Brabois, Vandoeuvre Lès Nancy, France.

Introduction: The significant morbidity and mortality in patients with heart failure (HF), notably in the most advanced forms of the disease, justify the need for novel therapeutic options. In the last year, the soluble guanylate cyclase (sGC) stimulator, vericiguat, has drawn the attention of the medical community following the report of reduced clinical outcomes in patients with worsening chronic HF (WCHF).

Areas Covered: The authors review the available data on the mechanism of action of vericiguat (cyclic guanosine monophosphate (cGMP) pathway), its clinical development program, its role in HF management, and its future positioning in the therapeutic recommendations. Read More

View Article and Full-Text PDF

Salivary Biomarkers for Diagnosis and Therapy Monitoring in Patients with Heart Failure. A Systematic Review.

Diagnostics (Basel) 2021 May 2;11(5). Epub 2021 May 2.

Second Department of Cardiology, Faculty of Medicine, School of Health Sciences, University of Ioannina and University Hospital of Ioannina, GR 45500 Ioannina, Greece.

The aim of this study was to perform a systematic review on the potential value of saliva biomarkers in the diagnosis, management and prognosis of heart failure (HF). The correlation between saliva and plasma values of these biomarkers was also studied. PubMed was searched to collect relevant literature, i. Read More

View Article and Full-Text PDF

Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure: A Health Technology Assessment.

Authors:

Ont Health Technol Assess Ser 2021 6;21(2):1-125. Epub 2021 May 6.

Background: Heart failure is a complex clinical syndrome that usually presents with breathlessness, leg edema, and fatigue. Clinically measurable natriuretic neurohormones such as B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are elevated in people with heart failure. We conducted a health technology assessment of BNP and NT-proBNP tests for people with suspected heart failure, which included an evaluation of diagnostic accuracy, clinical impact, cost-effectiveness, the budget impact of publicly funding BNP and NT-proBNP tests, and patient preferences and values. Read More

View Article and Full-Text PDF

Concentration-Dependent Clinical and Prognostic Importance of High-Sensitivity Cardiac Troponin T in Heart Failure and a Reduced Ejection Fraction and the Influence of Empagliflozin: the EMPEROR-Reduced Trial.

Eur J Heart Fail 2021 May 30. Epub 2021 May 30.

Université de Lorraine, Inserm INI-CRCT, CHRU, Nancy, France.

Background: Circulating troponin is an important measure of risk in patients with heart failure, but it has not been used to determine if disease severity influences the responses to drug treatments in randomized controlled trials.

Methods: In the EMPEROR-Reduced trial, patients with class II-IV heart failure and a reduced ejection fraction were randomly assigned to placebo or empagliflozin 10 mg daily and followed for the occurrence of serious heart failure and renal events. High-sensitivity cardiac troponin T (hs-cTnT) was measured in 3636 patients (> 97%) at baseline, and patients were divided into four groups based on the degree of troponin elevation. Read More

View Article and Full-Text PDF

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.

Eur J Heart Fail 2021 May 29. Epub 2021 May 29.

University of Glasgow, Glasgow, UK.

Aims: Sodium-glucose co-transporter 2 (SGLT2) inhibitors, originally developed as glucose-lowering agents, have been shown to reduce heart failure hospitalizations in patients with type 2 diabetes without established heart failure, and in patients with heart failure with and without diabetes. Their role in patients with heart failure with preserved and mildly reduced ejection fraction remains unknown.

Methods: Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure (DELIVER) is an international, multicentre, parallel group, event-driven, randomized, double-blind trial in patients with chronic heart failure and left ventricular ejection fraction (LVEF) >40%, comparing the effect of dapagliflozin 10 mg once daily, vs. Read More

View Article and Full-Text PDF

Association between N-terminal pro-BNP and 12 months major adverse cardiac events among patients admitted with NSTEMI.

Ann Palliat Med 2021 May 12;10(5):5231-5243. Epub 2021 May 12.

Department of Cardiology, Tianjin Chest Hospital, Tianjin, China.

Background: In recent years, the hospital admission rate of non-ST-elevation myocardial infarction (NSTEMI) patients has exhibited an increasing trend, and a forthcoming transition from ST-elevation myocardial infarction (STEMI) to NSTEMI has been observed in China. The association between serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) and major adverse cardiac events (MACEs) within 12 months after discharge among patients with NSTEMI remains unclear.

Methods: A total of 1,357 consecutively admitted NSTEMI patients were from the TAMI cohort. Read More

View Article and Full-Text PDF

Electronic Phenotyping to Identify Patients with Heart Failure Using a National Clinical Information Database in Japan.

Stud Health Technol Inform 2021 May;281:243-247

Medical IT Center, Tohoku University Hospital, Miyagi, Japan.

Heart failure (HF) is a grave problem in the clinical and public health sectors. The aim of this study is to develop a phenotyping algorithm to identify patients with HF by using the medical information database network (MID-NET) in Japan.

Methods: From April 1 to December 31, 2013, clinical data of patients with HF were obtained from MID-NET. Read More

View Article and Full-Text PDF

Prognostic value of prealbumin, N-terminal pro-B-type natriuretic peptide, heart type fatty acid binding protein, and cardiac troponin I in elderly patients for heart failure and poor outcomes.

J Int Med Res 2021 May;49(5):300060521999742

Department of Pathology, the Second Affiliated Hospital of Huzhou University, Huzhou, China.

Objectives: This study aimed to investigate the prognostic value of serum prealbumin, N-terminal pro-B-type natriuretic peptide (NT-proBNP), heart type fatty acid binding protein (hFABP), and cardiac troponin I (cTnI) for heart failure and cardiac death in elderly patients.

Methods: We studied 426 consecutive patients with New York Heart Association classes I to IV who were recruited between February 2014 and 2018. Cardiac mortality was the primary end point. Read More

View Article and Full-Text PDF

Getting to the Heart of the Matter: Myocardial Injury, Coagulopathy, and Other Potential Cardiovascular Implications of COVID-19.

Int J Vasc Med 2021 22;2021:6693895. Epub 2021 Apr 22.

Division of Biomedical Sciences, Marian University College of Osteopathic Medicine, Indianapolis, USA.

COVID-19 was primarily identified as a respiratory illness, but reports of patients presenting initially with cardiovascular complaints are rapidly emerging. Many patients also develop cardiovascular complications during and after COVID-19 infection. Underlying cardiovascular disease increases the severity of COVID-19 infection; however, it is unclear if COVID-19 increases the risk of or causes cardiovascular complications in patients without preexisting cardiovascular disease. Read More

View Article and Full-Text PDF

[Change of serum levels of pentraxin-3 and syndecan-4 in children with chronic heart failure].

Zhongguo Dang Dai Er Ke Za Zhi 2021 May;23(5):513-518

Department of Pediatrics, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.

Objective: To study the change and significance of serum pentraxin-3 (PTX-3) and syndecan-4 in children with chronic heart failure (CHF).

Methods: A total of 40 children with CHF who were admitted to the Department of Pediatrics of the First Affiliated Hospital of Zhengzhou University were enrolled as the heart failure group, and 30 children who underwent physical examination in the outpatient service during the same period of time were enrolled as the control group. The serum levels of PTX-3, syndecan-4, and N-terminal pro-brain natriuretic peptide (NT-proBNP) were compared between the two groups. Read More

View Article and Full-Text PDF

Narrative review of metabolomics in cardiovascular disease.

J Thorac Dis 2021 Apr;13(4):2532-2550

First Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany.

Cardiovascular diseases are accompanied by disorders in the cardiac metabolism. Furthermore, comorbidities often associated with cardiovascular disease can alter systemic and myocardial metabolism contributing to worsening of cardiac performance and health status. Biomarkers such as natriuretic peptides or troponins already support diagnosis, prognosis and treatment of patients with cardiovascular diseases and are represented in international guidelines. Read More

View Article and Full-Text PDF

Routine use of natriuretic peptides: Lessons from a big data analysis.

Ann Clin Biochem 2021 Jun 2:45632211020779. Epub 2021 Jun 2.

Cardiology Department, Avicenne University Hospital, APHP, Université Sorbonne Paris Nord, Bobigny, France.

Background: Natriuretic peptides have broad indications during heart failure and the detection of left ventricular dysfunction in high-risk patients. They can also be used for the diagnosis/management of other cardiac diseases. However, very little is known regarding their use in routine practice. Read More

View Article and Full-Text PDF

Timely and individualized heart failure management: need for implementation into the new guidelines.

Clin Res Cardiol 2021 May 13. Epub 2021 May 13.

Klinik Für Innere Medizin III-Kardiologie, Angiologie Und Internistische Intensivmedizin, Universitätsklinikum Des Saarlandes, Kirrberger Strasse 100, 66421, Homburg, Germany.

Due to remarkable improvements in heart failure (HF) management over the last 30 years, a significant reduction in mortality and hospitalization rates in HF patients with reduced ejection fraction (HFrEF) has been observed. Currently, the optimization of guideline-directed chronic HF therapy remains the mainstay to further improve outcomes for patients with HFrEF to reduce mortality and HF hospitalization. This includes established device therapies, such as implantable defibrillators and cardiac resynchronization therapies, which improved patients' symptoms and prognosis. Read More

View Article and Full-Text PDF

Advancements in biomarkers for cardiovascular disease: diagnosis, prognosis, and therapy.

Fac Rev 2021 31;10:34. Epub 2021 Mar 31.

Division of Cardiovascular Medicine, University of California San Diego, La Jolla, CA, USA.

Biomarkers are essential tools in the practice of cardiology. They assist with diagnosis, prognosis, and guiding therapy in many different cardiovascular diseases. Numerous biomarkers have become strongly associated with different cardiovascular conditions, such as troponin with acute coronary syndrome and natriuretic peptides with heart failure. Read More

View Article and Full-Text PDF

Comprehensive plasma metabolomic and lipidomic analyses reveal potential biomarkers for heart failure.

Mol Cell Biochem 2021 May 11. Epub 2021 May 11.

Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, No. 49, Hua Yuan North Rd, Hai Dian District, Beijing, 100191, China.

Heart failure is a syndrome with symptoms or signs caused by cardiac dysfunction. In clinic, four stages (A, B, C, and D) were used to describe heart failure progression. This study was aimed to explore plasma metabolomic and lipidomic profiles in different HF stages to identify potential biomarkers. Read More

View Article and Full-Text PDF

CNP regulates cardiac contractility and increases cGMP near both SERCA and TnI - difference from BNP visualized by targeted cGMP biosensors.

Cardiovasc Res 2021 May 10. Epub 2021 May 10.

Department of Pharmacology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, P.O.Box 1057 Blindern, 0316 Oslo, Norway.

Aims: Guanylyl cyclase-B (GC-B; natriuretic peptide receptor-B, NPR-B) stimulation by C-type natriuretic peptide (CNP) increases cGMP and causes a lusitropic and negative inotropic response in adult myocardium. These effects are not mimicked by NPR-A (GC-A) stimulation by brain natriuretic peptide (BNP), despite similar cGMP increase. More refined methods are needed to better understand the mechanisms of the differential cGMP signaling and compartmentation. Read More

View Article and Full-Text PDF

[Biomarkers for the diagnosis and management of heart failure: new frontiers].

G Ital Cardiol (Rome) 2021 May;22(5):386-396

Istituto di Scienze della Vita, Scuola Superiore Sant'Anna, Pisa - Fondazione Toscana Gabriele Monasterio, Pisa.

Heart failure (HF) has a complex pathophysiology including neurohormonal activation, inflammation and oxidative stress that, together with comorbidities, promote progressive myocardial damage and cardiac remodeling. Over the years the study of these pathogenic mechanisms has led to the identification of several analytes potentially useful as biomarkers in HF. High-sensitivity troponins and soluble suppression of tumorigenesis-2 are the most promising biomarkers for risk stratification of HF, with independent value to natriuretic peptides. Read More

View Article and Full-Text PDF

Interdisciplinary assessment and diagnostic algorithm: The role of the cardiologist.

Diabetes Res Clin Pract 2021 May 4;176:108851. Epub 2021 May 4.

St George's Hospital Medical School, London, United Kingdom; IRCCS San Raffaele Roma, Italy; St Heliers and Epsom Hospital, United Kingdom.

Patients with diabetes have an increased risk of developing heart failure and those with heart failure are at higher risk of developing diabetes. In patients with diabetes antidiabetic medications and the metabolic alterations of diabetes increase the risk of developing heart failure. In diabetic patients with heart failure and in those with an increased likelihood of developing the disease a stepwise approach based on the use of natriuretic peptides and echocardiography to rule out the presence of heart failure should be used. Read More

View Article and Full-Text PDF

Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction.

Clin Res Cardiol 2021 May 6. Epub 2021 May 6.

Université de Lorraine, Centre D'Investigations Cliniques-INSERM CHRU de Nancy, Institut Lorrain du Coeur Et Des Vaisseaux Louis Mathieu, 4 rue du Morvan, 54500, Vandoeuvre lès Nancy, France.

Background: Loop diuretics are the mainstay of congestion treatment in patients with heart failure (HF). We assessed the association between baseline loop diuretic use and outcome. We also compared the increment in risk related to diuretic dose with conventional prognostic enrichment criteria used in the EMPHASIS-HF trial, which included patients with systolic HF and mild symptoms, such as prior hospitalization and elevated natriuretic peptides. Read More

View Article and Full-Text PDF

COVID-19 Cardiac Injury: An Important Cause of COVID-19 Related Morbidityand Mortality.

Ann Clin Lab Sci 2021 Mar;51(2):156-162

Department of Pathology and Laboratory Medicine, University of Texas McGovern Medical School at Houston, Houston, TX, USA

Objective: Although coronavirus disease 2019 (COVID-19) typically presents as a respiratory illness, co-existent cardiovascular symptomatology associated with an elevated serum troponin level has been identified as a risk factor for adverse outcomes. Our study addressed the need to correlate serum cardiovascular biomarkers with tissue pathology based on autopsy.

Materials And Methods: In 13 patients, we reviewed the clinical history and measurements of serum troponin and other biomarkers and correlated them with autopsy findings. Read More

View Article and Full-Text PDF

Sex-specific temporal evolution of circulating biomarkers in patients with chronic heart failure with reduced ejection fraction.

Int J Cardiol 2021 Jul 30;334:126-134. Epub 2021 Apr 30.

Department of Cardiology, Erasmus Medical Centre, Rotterdam, the Netherlands. Electronic address:

Background: We aimed to assess differences in clinical characteristics, prognosis, and the temporal evolution of circulating biomarkers in male and female patients with HFrEF.

Methods: We included 250 patients (66 women) with chronic heart failure (CHF) between 2011 and 2013 and performed trimonthly blood sampling during a median follow-up of 2.2 years [median (IQR) of 8 (5-10) urine and 9 (5-10) plasma samples per patient]. Read More

View Article and Full-Text PDF

A Low-Sodium Diet Boosts Ang (1-7) Production and NO-cGMP Bioavailability to Reduce Edema and Enhance Survival in Experimental Heart Failure.

Int J Mol Sci 2021 Apr 14;22(8). Epub 2021 Apr 14.

Department of Medicine, University of Arizona College of Medicine-Phoenix, Phoenix, AZ 85004, USA.

Sodium restriction is often recommended in heart failure (HF) to block symptomatic edema, despite limited evidence for benefit. However, a low-sodium diet (LSD) activates the classical renin-angiotensin-aldosterone system (RAAS), which may adversely affect HF progression and mortality in patients with dilated cardiomyopathy (DCM). We performed a randomized, blinded pre-clinical trial to compare the effects of a normal (human-equivalent) sodium diet and a LSD on HF progression in a normotensive model of DCM in mice that has translational relevance to human HF. Read More

View Article and Full-Text PDF

Hypertrophy-Reduced Autophagy Causes Cardiac Dysfunction by Directly Impacting Cardiomyocyte Contractility.

Cells 2021 Apr 4;10(4). Epub 2021 Apr 4.

DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, 10785 Berlin, Germany.

Cardiac remodeling and contractile dysfunction are leading causes in hypertrophy-associated heart failure (HF), increasing with a population's rising age. A hallmark of aged and diseased hearts is the accumulation of modified proteins caused by an impaired autophagy-lysosomal-pathway. Although, autophagy inducer rapamycin has been described to exert cardioprotective effects, it remains to be shown whether these effects can be attributed to improved cardiomyocyte autophagy and contractility. Read More

View Article and Full-Text PDF

Mortal Interaction Between Hemophagocytic Syndrome and Newly Developed Heart Failure.

Arq Bras Cardiol 2021 03;116(3):395-401

Health Sciences University, Adana Research and Training Hospital - Department of Cardiology, Adana - Turquia.

Background: Hemophagocytic syndrome (HPS) ia s devastating hyperinflammatory syndrome. Heart failure (HF) with preserved ejection fraction (HFpEF) status is closely correlated with increased inflammation, both systemic and intramyocardial.

Objectives: This study sought to determine mortality predictors and reliable follow-up parameters in HPS that developed HFpEF during the clinical course. Read More

View Article and Full-Text PDF

Valsartan Dosage on Ventriculo-Vascular Coupling Index Dose-Dependency in Heart Failure Patients.

Yonsei Med J 2021 May;62(5):391-399

Gachon Cardiovascular Research Institute, Gachon University, Incheon, Korea.

Purpose: Heart failure (HF) poses significant morbidity and mortality. Recently, the ventriculo-vascular coupling index (VVI) was introduced as an independent prognostic factor reflective of the overall cardiovascular performance index in HF. We aimed to determine the effectiveness of force-titration of valsartan on VVI values in HF patients. Read More

View Article and Full-Text PDF

The role of recombinant human brain natriuretic peptide on the cardiac output of patients with acute decompensated heart failure using Guyton venous return curve: A STROBE-compliant retrospective study.

Medicine (Baltimore) 2021 Apr;100(17):e25492

Department of Intensive Care Unit, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

Abstract: rbBNP has positive cardiac effects in patients with acute decompensated heart failure, but its effects on the systemic venous circulation are not known.A single-center retrospective, self-controlled study was conducted on 14 patients undergone recombinant human brain natriuretic peptide (rhBNP) treatment between January 1, 2015 to December 31, 2018.The cardiac output (CO) significantly increased from 3. Read More

View Article and Full-Text PDF